Letter to the Editor: Leucine-rich α-2-glycoprotein in Taiwanese inflammatory bowel disease: Strengths and limitations of a novel serum marker

doi:10.3748/wjg.v32.i18.117611

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 32, Issue 18

This Article

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (23)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-2) series, Tables (1-1) series.

Item

Count

PDF

HTML

Figures (1-2)

Tables (1-1)

Sum=56

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

Download

Sum=41

May 14, 2026 (publication date) through May 6, 2026

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Correspondence

Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.

World J Gastroenterol. May 14, 2026; 32(18): 117611
Published online May 14, 2026. doi: 10.3748/wjg.v32.i18.117611

Letter to the Editor: Leucine-rich α-2-glycoprotein in Taiwanese inflammatory bowel disease: Strengths and limitations of a novel serum marker

Rupa Guha, Aditi Banerjee

Rupa Guha, Department of Radiation Oncology, University of California, San Francisco, CA 94143, United States

Aditi Banerjee, Department of Pediatrics, University of Maryland School of Medicine, Baltimore, MD 21201, United States

Aditi Banerjee, Cancer Comprehensive Center, University of Maryland, Marlene and Stewart Greenebaum Comprehensive Cancer Center, Baltimore, MD 21201, United States

Author contributions: Guha R wrote the original work and prepared the figures, reviewed and edited the manuscript; Banerjee A conceptualized the work, wrote the original draft, and reviewed and approved the final version.

Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.

Corresponding author: Aditi Banerjee, PhD, Associate Professor, Department of Pediatrics, University of Maryland School of Medicine, 655 West Baltimore Street, Baltimore, MD 21201, United States. aditi.banerjee@som.umaryland.edu

Received: December 11, 2025
Revised: February 2, 2026
Accepted: March 3, 2026
Published online: May 14, 2026
Processing time: 146 Days and 10.3 Hours

Core Tip

Core Tip: Leucine-rich α-2-glycoprotein (LRG) is an emerging serum biomarker that showed modest but incremental value for predicting endoscopic activity in Taiwanese patients with ulcerative colitis and Crohn’s disease, particularly when combined with C-reactive protein, hemoglobin, and albumin. This Letter highlights methodological issues and clinical implications of LRG testing, including its lower accuracy than fecal calprotectin, single-center data, and lack of standardized cutoffs, and argues that future multicenter, multi-ethnic studies should position LRG within composite biomarker panels and stepwise algorithms for noninvasive assessment of inflammatory bowel disease activity.